-
1 week ago | 
healio.com | Jay Chhablani |Cory Perla
SALT LAKE CITY — In this video, Jay Chhablani, MD, professor of ophthalmology at University of Pittsburgh School of Medicine, discusses 24-month findings from the SAGA trial evaluating oral gildeuretinol for geographic atrophy. Daily 14 mg gildeuretinol (Alkeus Pharmaceuticals) was associated with a reduction in GA lesion growth, with greater reductions occurring between months 6 and 24, Chhablani said. Patients also had less visual acuity loss and improved quality of life scores, he said.
-
2 weeks ago | 
healio.com | Jay Chhablani |Cory Perla
SALT LAKE CITY — In this video, Jay Chhablani, MD, discusses findings presented at the ARVO meeting from a phase 2b study evaluating suprachoroidal axitinib for neovascular age-related macular degeneration. The trial enrolled 60 previously treated patients with stable vision and compared suprachoroidal axitinib (Clearside Biomedical) with intravitreal aflibercept 2 mg (Regeneron).
-
Feb 24, 2025 | 
healio.com | Cory Perla |Mindy Valcarcel
SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.
-
Feb 19, 2025 | 
healio.com | Cory Perla |Mindy Valcarcel
SAN DIEGO — In this video, Jennifer A. Woyach, MD, discusses a phase 3 randomized trial comparing pirtobrutinib to idelalisib or bendamustine plus rituximab for chronic lymphocytic leukemia pretreated with Bruton tyrosine kinase inhibitor.
-
Feb 17, 2025 | 
healio.com | Cory Perla |Mindy Valcarcel
Source: Healio Interviews Disclosures: Woyach reports serving in consulting roles for AstraZeneca, AbbVie, Genentech, Janssen, Loxo Lilly, Merck, Newave Pharmaceutical, Pharmacyclics and Schrödinger.
-
Feb 5, 2025 | 
healio.com | Marlise R. Luskin |Marley Ghizzone |Cory Perla |Mindy Valcarcel
SAN DIEGO — Marlise R. Luskin, MD, MSCE, speaks with Healio about findings from the phase 3 randomized Alliance A041501 trial. The study was put on hold due to grade 5 events among patients who received inotuzumab (Besponsa, Pfizer) and progressed onto chemotherapy, according to the abstract.
-
Feb 3, 2025 | 
healio.com | Marlise R. Luskin |Marley Ghizzone |Cory Perla |Mindy Valcarcel
SAN DIEGO — In this video, Marlise R. Luskin, MD, MSCE, discusses results from a phase 3 randomized trial that investigated the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia.
-
Jan 16, 2025 | 
healio.com | Cory Perla |Christine Klimanskis
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this video from the AAO meeting, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses the role of AREDS vitamins in slowing the progression of geographic atrophy.
-
Jan 16, 2025 | 
healio.com | Cory Perla |Christine Klimanskis
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses highlights from the AAO meeting, including presentations on pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.
-
Jan 14, 2025 | 
healio.com | Cory Perla |Christine Klimanskis
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses a presentation from the AAO meeting on multimodal imaging to assess geographic atrophy.
